Navigation Links
NuVasive Licenses Its 'Insert and Rotate' Technology
Date:10/8/2007

SAN DIEGO, Oct. 8 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today the license of its "insert and rotate" method technology to Theken Spine, LLC.

Under the agreement, Theken Spine was granted a non-exclusive license to use NuVasive's patented "insert and rotate" method of US Patent No. 6,290,724 in exchange for royalty payments to be made to NuVasive. The patented "insert and rotate" method is a means of inserting a device between adjacent vertebrae and then rotating the device for the purpose of separating and stabilizing those vertebrae.

Commenting on the patent license agreement, Alexis V. Lukianov, Chairman and Chief Executive Officer, said, "We view this license arrangement as a solid validation of our unique and growing Intellectual Property platform. We commend Theken Spine for their cooperation in working to conclude this agreement."

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $3.6 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS, as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the risk that we could become engaged in litigation concerning our intellectual property, including the risk our patents (including patents covering our "insert and rotate" technology) could be invalidated because of unknown prior art or other reasons; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at http://www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Contact:

Kevin C. O'Boyle

EVP & Chief Financial Officer

NuVasive, Inc.

investorrelations@nuvasive.com

Investors:

Nick Laudico / Zack Kubow

The Ruth Group

646-536-7030 / 7020

nlaudico@theruthgroup.com

zkubow@theruthgroup.com

Media:

Jason Rando

The Ruth Group

646-536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE NuVasive, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. US Government Licenses New Hypertension Drug
2. Panacea Biotec In-Licenses FMD Vaccine
3. Thailand Goes Ahead With Licenses for Generic Drugs
4. Swedish Biotech Licenses HIV Drug to China for Development
5. More Foreign Trained Doctors Receive Licenses
6. FDA Licenses First US Vaccine Against Avian Flu
7. Thailand Will Not Issue Compulsory Licenses for Patented Drugs
8. Spacer Insertion May Offer Less Invasive Option for Lumbar Problems
9. RotaTeq Gets US Approval
10. Vedic vibration technology- the new cure for arthritis
11. Biotechnology industry expected to grow into a three billion dollar industry by 2002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... HealthiPASS, Inc., announces ... creating a positive patient experience. , HealthiPASS has further enhanced its predictive ... by helping them understand their financial responsibility. “Our latest release focuses on ...
(Date:3/22/2017)... CA (PRWEB) , ... March 22, 2017 , ... Nearly ... should not undergo PSA (prostate-specific antigen) screening, the cancer screening continues to stir controversy. ... 2008 because it found that the risks outweighed the benefits. Now, news from ...
(Date:3/22/2017)... ... , ... The National Association for Business Resources (NABR) has recently ... in Wellness® companies for 2017. , American Specialty Health (ASH) was honored ... for its employees. ASH is one of only nine other San Diego companies being ...
(Date:3/22/2017)... ... March 22, 2017 , ... Winter ... reduces pigmentation to enhance surgical and nonsurgical procedures—Lytera 2.0 by SkinMedica. Lytera 2.0 ... the face, neck and décolletage in as little as 4 weeks. Skin pigmentation ...
(Date:3/20/2017)... ... ... The topic of healthcare in America has become one of the most ... is that they are still left without the health insurance coverage they need in ... that an unfortunate side-effect of this scenario is that hospital emergency rooms and urgent ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... GROVE, Minn. , March 22, 2017   Upsher-Smith ... Clomipramine Hydrochloride Capsules* USP, 25 mg, 50 mg and 75 ... (clomipramine hydrochloride) Capsules USP. The clomipramine hydrochloride ... the 12 months ending December 2016, according to IMS Health. ... "Upsher-Smith ...
(Date:3/22/2017)... , March 22, 2017  Levine Cancer Institute ... (CT) unit designed to address lung cancer diagnosis, ... the Carolinas. The mobile lung unit is the ... education and treatment interventions through integrated mobile technology, ... Financial barriers and a lack of public ...
(Date:3/22/2017)...  Varex Imaging Corporation (Nasdaq: VREX ) ... pricing agreement with Toshiba Medical Systems under which Varex ... tubes for integration into Toshiba Medical,s CT imaging systems ... effective April 1, 2017. Potential sales of ... to be in the range of $345 million to ...
Breaking Medicine Technology: